Abbott Laboratories (ABT)

NYSE: ABT · USD

$103

-0.44 (-0.4%)· Recorded snapshot

英文原文ZH

翻译期间显示英文原文

此报告尚未翻译。翻译队列赶上后请在几分钟内刷新。

StockMarketAgent Research · Analyzed 2026-09-09

Our latest published analysis: ABT rated Reduce

Abbott Laboratories's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$86.7 / share

Potential value

$140 / share

Upside to FV

-17.8%

from $103

Moat

1/10

None

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$183.8B
Revenue (ttm)	48.2B
Net income (ttm)	4.7B
EPS (ttm)	$2.69
Shares out	1.7B
P/E (trailing)	38.2x
P/E (forward)	17.9x
Dividend	$2.52 (2.45%)
Volume	4,052,721
Beta	0.58

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 48.2B
Net income (ttm): 4.7B
EPS (ttm): $2.69
P/E (trailing): 38.2x
P/E (forward): 17.9x
Market cap: $183.8B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$43.08B	$43.65B	$40.11B	$41.95B	$44.33B	+0.7%
Gross profit	$23.21B	$22.32B	$20.04B	$21.33B	$24.61B	+1.5%
Operating income	$8.43B	$8.36B	$6.48B	$6.83B	$8.05B	-1.1%
Net income	$7.07B	$6.93B	$5.72B	$13.40B	$6.52B	-2.0%
EPS (diluted)	$3.94	$3.91	$3.26	$7.64	$3.72	-1.4%
EBITDA	$12.16B	$11.89B	$10.61B	$10.83B	$11.55B	-1.3%
R&D	$2.74B	$2.89B	$2.74B	$2.84B	$2.94B	+1.8%
SG&A	$11.32B	$11.25B	$10.95B	$11.70B	$12.33B	+2.2%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	卖出
ACN	Accenture plc	144.3B	18.0x	2.0x	27.9%	+8.0%	+0.4%	持有
ADI	Analog Devices, Inc.	207.6B	50.9x	14.8x	11.0%	+16.4%	+76.9%	卖出
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	减持
ALNY	Alnylam Pharmaceuticals, Inc.	31.1B	41.4x	6.4x	96.6%	+47.5%	-52.1%	强力买入
AMGN	Amgen Inc.	244.2B	28.1x	6.4x	19.8%	+8.4%	+58.6%	买入

Base and Bull scenarios

Base60%

Price target

$86.74

-17.8% from spot

The base scenario assumes the FY2027 revenue and adjusted-EPS forecasts are achieved. It then assumes growth fades toward a mature-company pace; that post-FY2027 fade is a valuation premise, not a reported result.

FY2027 revenue and adjusted EPS remain within their published ranges.
The house valuation assumes growth settles toward a mature-company pace after FY2027; this is an assumption rather than a reported result.

Bull20%

Price target

$139.69

+32.4% from spot

Broader growth persistence would lift revenue, earnings, and cash beyond the period directly supported by dated forecasts.

The bull scenario requires Medical Devices to grow faster than Abbott after FY2027; FY2025 segment revenue establishes scale, not growth persistence.
It also assumes Diagnostics, Nutrition, and Established Pharmaceuticals continue contributing positively while free cash flow stays positive. Each named segment reported positive FY2025 operating income, and FY2025 free cash flow was positive.

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($86.74). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	1.5%	2.0%	2.5%	3.0%	3.5%
5.3%	$99.9	$106	$115	$127	$146
6.3%	$87.9	$91.7	$96.6	$103	$111
7.3%	$79.6	$82.1	$86.7	$88.8	$93.4
8.3%	$73.4	$75.2	$77.2	$79.6	$82.5
9.3%	$68.7	$69.9	$71.4	$73.0	$74.9

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E17.9

P25 n/aP50 n/aP75 n/a

Trailing P/E34.2

P25 n/aP50 n/aP75 n/a

ROE10.6

P25 n/aP50 n/aP75 n/a

ROIC7.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ABT indicators

Market & fundamental data

Available fields

275

Groups with data

Currency

USD

Showing 275 of 275 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000001800
Company name	Abbott Laboratories
Country	United States
Country code	US
CUSIP number	002824100
Earnings date	2026-10-21
Earnings time	bmo
Employees	115,000
Employees change	1,000
Employees growth	0.88%
Enterprise value	$204.8B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-09-30
First seen	2026-05-09
Fiscal year end	December
Founded	1888
In index	SP500
Industry	Medical Devices
Is primary listing	Yes
Is SPAC	No
ISIN number	US0028241000
Last 10-K release date	2026-02-20
Last earnings date	2026-10-21
Last refreshed	2026-10-28
Last stock split date	1998-06-01
Last stock split type	Forward
Market cap	$177.6B
Market cap category	Large-Cap
Next earnings date	2027-01-21
Options	Yes
Price	$102.66
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ABT
U.S. state	Illinois
Website	https://www.abbott.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	19.08x
Average P/E ratio (10Y)	50.21x
Average P/E ratio (3Y)	27.41x
Average P/E ratio (5Y)	28.1x
Earnings yield	2.62%
EV/Earnings	43.94x
EV/EBIT	25.75x
EV/EBITDA	17.19x
EV/FCF	26.27x
EV/Sales	4.26x
FCF / EV yield	3.81%
FCF yield	4.39%
Forward EV/Sales	3.89x
Forward P/E	17.61x
Forward P/S	3.37x
Graham number	42.28614
Graham upside	-58.98%
Industry forward P/E	19.81x
Industry P/E	39.28x
Lynch fair value	$13.45
Lynch upside	-86.95%
P/(FCF - SBC) ratio	25.1x
P/(OCF - SBC) ratio	19.42x
P/B ratio	3.49x
P/E ratio	38.15x
P/FCF ratio	22.8x
P/OCF ratio	18.01x
P/S ratio	3.7x
PEG ratio	1.88x
Price/EBITDA ratio	14.92x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	16.55%
EBITDA margin	24.79%
Effective tax rate	28.36%
FCF margin	16.8%
Gross margin	57.08%
Operating margin	16.55%
Pretax margin	13.61%
Profit margin	9.75%
Profit per employee	$40,670
Profitable quarters	34
Profitable years	35
Revenue per employee	$419,383
ROA	5.33%
ROA (5Y)	6.84%
ROCE	9.01%
ROE	10.58%
ROE (5Y)	19.7%
ROIC	7.25%
ROIC (5Y)	14.92%
SBC / revenue	1.54%
Tax / revenue	3.86%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-66.24%
EPS growth (Q)	-43.69%
EPS growth (QoQ)	-0.12%
EPS growth 10Y	11.38%
EPS growth 3Y	-2.87%
EPS growth 5Y	-7.76%
EPS growth years	0
FCF growth	15.48%
FCF growth 3Y	12.55%
FCF growth 5Y	-1.97%
Gross profit growth	12.07%
Gross profit growth (Q)	17.95%
Gross profit growth 3Y	7.75%
Gross profit growth 5Y	2.62%
Net income growth	-66.37%
Net income growth (Q)	-44.04%
Net income growth (QoQ)	-0.86%
Net income growth 3Y	-3.11%
Net income growth 5Y	-8.3%
Net income growth years	0
OCF growth	9.61%
OCF growth 10Y	13.31%
OCF growth 3Y	9.95%
OCF growth 5Y	-1.4%
Operating income growth	-5.19%
Operating income growth (Q)	-33.06%
Operating income growth 3Y	5.37%
Operating income growth 5Y	-2.23%
Revenue growth	10%
Revenue growth (Q)	14.46%
Revenue growth (QoQ)	3.34%
Revenue growth 10Y	8.82%
Revenue growth 3Y	6.47%
Revenue growth 5Y	2.65%
Revenue growth quarters	11
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-2.1B
Depreciation and amortization	$4B
EBIT	$8B
EBITDA	$12B
EPS	$2.69
FCF per share	$4.52
Financing cash flow	$10.6B
Free cash flow	$7.8B
Free cash flow minus SBC	$7.1B
Gross profit	$27.5B
Income taxes	$1.9B
Investing cash flow	$-22.4B
Net borrowing	$16.5B
Net cash flow	$-1.8B
Net income	$4.7B
Operating cash flow minus SBC	$9.2B
Operating income	$8B
Revenue	$48.2B
Stock-based compensation	$718M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$29.54
Debt / EBITDA	2.65
Debt / equity	0.63
Debt / FCF	4.18
Interest coverage	7.87
Net cash (debt)	$-27.1B
Net cash / market cap	-15.2%
Net debt / EBITDA	2.27
Net debt / equity	0.52
Net debt / FCF	3.47
Piotroski F-Score	5
Shareholders' equity	$51.8B
Tangible book value	$-1.3B
Tangible book value per share	$-0.78
Total cash	$5.6B
Total debt	$32.7B
WACC	6.65%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.48
Current ratio	1.38
Inventory turnover	2.82
Quick ratio	0.8
Working capital	$6.7B

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.25%
Dividend growth	6.78%
Dividend growth (10Y)	9.25%
Dividend growth (3Y)	7.3%
Dividend growth (5Y)	6.96%
Dividend growth years	54
Dividend payment date	2026-11-16
Dividend payment years	56
Dividend payout frequency	Quarterly
Dividend per share	$2.52
Dividend yield	2.45%
Ex-dividend date	2026-10-15
FCF payout ratio	55.73%
Last dividend	$0.63
Payout ratio	93.66%
Shareholder yield	2.69%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	154.93%
10Y return CAGR	11.9%
10Y total return	207.67%
150-day SMA	$98.57
15Y price change	89.75%
15Y return CAGR	11.87%
15Y total return	437.68%
1D price change	-0.43%
1M price change	1.4%
1M total return	2.03%
1W price change	0.25%
1W total return	0.25%
1Y price change	-19.24%
1Y return CAGR	-17.24%
1Y total return	-17.23%
20-day SMA	$101.51
200-day SMA	$101.89
20Y price change	115.46%
20Y return CAGR	10.31%
20Y total return	611.22%
3M price change	-1.7%
3M total return	-1.1%
3Y price change	10.62%
3Y return CAGR	5.62%
3Y total return	17.82%
50-day SMA	$104.70
50-day SMA vs 200-day SMA	50over200
52-week high	$132.03
52-week high date	2025-11-18
52-week low	$81.97
52-week low date	2026-05-11
5Y price change	-19.58%
5Y return CAGR	-2.34%
5Y total return	-11.16%
6M price change	10.68%
6M total return	12.15%
All-time high	$142.60
All-time high date	2021-12-27
All-time low	$0.24
All-time low date	1974-10-04
Average true range (ATR)	$2.81
Average volume	9.8M
Beta (1Y)	-0.45
Beta (2Y)	0.08
Beta (5Y)	0.58
Change from 52-week high	-22.24%
Change from 52-week low	25.24%
Change from all-time high	-27.97%
Change from all-time low	43,001.13%
Change from open	0.8%
Day's gap	-1.21%
Dollar volume	$416.1M
High price	$103.91
Low price	$101.83
Monthly RSI	45.66
Open price	$101.85
Position in 52-week range	39.9%
Premarket change	-1.31%
Premarket close	$103.10
Premarket price	$101.75
Premarket volume	1.3K
Previous close	$103.10
Price vs 150-day SMA	4.2%
Price vs 20-day SMA	1.18%
Price vs 200-day SMA	0.81%
Price vs 50-day SMA	-1.9%
Relative volume	0.41
RSI	50.17
Sharpe ratio	-0.7
Sharpe ratio (3Y)	0.13
Sharpe ratio (5Y)	-0.13
Sortino ratio	-0.78
Sortino ratio (3Y)	0.44
Sortino ratio (5Y)	0.06
Volume	4.1M
Weekly RSI	48.92
YTD price change	-18.02%
YTD total return	-15.98%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.7B
Float percentage	99.39%
Shares change (QoQ)	-0.29%
Shares change (YoY)	-0.25%
Shares held by insiders	0.5%
Shares held by institutions	80.99%
Shares outstanding	1.7B
Short % of float	0.79%
Short % of shares	0.79%
Short ratio	1.6 days

Other indicators

Additional ticker metrics that do not fit the primary research groupings.

Metric	Value
Page views	180

Deeper analysis on ABT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this ABT report

What is the latest published ABT stock rating?

Abbott Laboratories is shown with Reduce in the latest published report, analyzed 2026-09-09. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ABT analysis?

The full latest published report, analyzed 2026-09-09, lives at /stocks/ABT/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for ABT?

The latest published report analyzed 2026-09-09 gives ABT a fair value of USD 87 and a potential value of USD 140. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the ABT page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-09-09). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

ReduceABT · Fair value $86.7-17.8%

Read full analysis →

Category	Score	Reading
Valuation	3.0
Management	6.5
Balance Sheet	6.0
Profitability	5.5
Revenue Growth	6.0
Risk Assessment	7.5
Competitive Moat	1.0
Earnings Quality	6.0
Capital Efficiency	5.5

Abbott Laboratories (ABT)

Our latest published analysis: ABT rated Reduce

Price

Financial snapshot

Fair-value bridge

Latest news · ABT

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All ABT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Other indicators

Deeper analysis on ABT

Frequently asked questions

评级历史